Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Core Viewpoint - Dyadic International, Inc. has announced the pricing of its public offering of 6,052,000 shares of common stock, with the closing expected on August 1, 2025, subject to customary conditions [1]. Company Overview - Dyadic International, Inc. is a global biotechnology company focused on scalable production of high-value, precision-engineered functional input proteins for life sciences, food and nutrition, and industrial biotechnology applications [1][5]. - The company utilizes proprietary gene expression platforms to produce recombinant proteins, which are sold or licensed to partners across various markets [5]. Offering Details - The public offering is being managed solely by Craig-Hallum Capital Group LLC [2]. - The net proceeds from the offering will be used for working capital and general corporate purposes, including product development, sales, and marketing [2]. - The offering is conducted under an effective shelf registration statement filed with the SEC [3]. Contact Information - For inquiries, Dyadic Applied BioSolutions can be contacted through Ping W. Rawson, Chief Financial Officer, at (561) 743-8333 or via email at ir@dyadic.com [8].